IGC-1C

About IGC Pharma

IGC Pharma is a clinical-stage biotechnology company with a mission to develop novel treatments and AI-driven tools for Alzheimer's disease. Its primary achievement is the advancement of lead candidate IGC-AD1 into a Phase 2 trial (CALMA) targeting Alzheimer's-related agitation, a significant unmet need. The company's strategy uniquely combines therapeutic development of small molecules targeting neuroinflammation and amyloid/tau pathology with a proprietary artificial intelligence platform designed for early prediction and personalized care. Operating as a micro-cap public company, IGC seeks to address a massive and growing market through this integrated, technology-enhanced approach.

Therapeutic Areas